1 min read
Add as a preferred source on GoogleVicore Pharma Posts Q3 Loss of SEK 0.44 Per Share as Revenue Falls 25%
Net loss widened to SEK 124.3 million, and cash, cash equivalents and short-term investments totaled SEK 772 million at Sept. 30, 2026.
Vicore Pharma Holding AB (publ) posted a GAAP loss of SEK 0.44 per share for the third quarter of 2026 as revenue fell 25% from a year earlier to SEK 0.6 million.
The company’s net loss widened to SEK 124.3 million from SEK 113.5 million in the third quarter of 2025. Its operating loss grew to SEK 133.3 million from SEK 116 million.
Cash, cash equivalents and short-term investments totaled SEK 772 million at Sept. 30, 2026.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.